Impaired inactivation of L-type Ca2+ current as a potential mechanism for variable arrhythmogenic liability of herg K+ channel blocking drugs

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Kim, Jae Gon ^a,b   Sung, Dong Jun ^d   Kim, Hyun Ji ^a   Park, Sang Woong ^d   Won, Kyung Jong ^d   Kim, Bokyung ^d   Shin, Ho Chul ^e   Kim, Ki Suk ^b,c   Leem, Chae Hun ^f   Zhang, Yin Hua ^g   Cho, Hana ^a   Bae, Young Min ^d  

^a Samsung Medical Center   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

^c University of Science and Technology (UST)   (South Korea)

^d Konkuk University   (South Korea)

^e Konkuk University   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

^g Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; BARIUM ION; CALCIUM CHANNEL L TYPE; CIPROFLOXACIN; ENOXACIN; KETOCONAZOLE; LATE CALCIUM CHANNEL L TYPE; LEVOFLOXACIN; OFLOXACIN; POTASSIUM CHANNEL BLOCKING AGENT; SPARFLOXACIN; UNCLASSIFIED DRUG; ANTIARRHYTHMIC AGENT; POTASSIUM CHANNEL HERG; QUINOLONE DERIVATIVE;

ACTION POTENTIAL; ACTION POTENTIAL DURATION; ANIMAL CELL; ARRHYTHMOGENESIS; ARTICLE; CALCIUM DEPENDENT INACTIVATION; CALCIUM SIGNALING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPOLARIZATION; DRUG EXPOSURE; EXTRACELLULAR CALCIUM; INFANT; MEMBRANE STEADY POTENTIAL; MOUSE; MUSCLE CELL; NEWBORN; NONHUMAN; QT PROLONGATION; RAT; REPOLARIZATION; STEADY STATE; TORSADE DES POINTES; ANIMAL; CARDIAC MUSCLE CELL; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; HEART CONTRACTION; HEART VENTRICLE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; SPRAGUE DAWLEY RAT;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNELS, L-TYPE; CALCIUM SIGNALING; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; ETHER-A-GO-GO POTASSIUM CHANNELS; FLUOROQUINOLONES; HEART VENTRICLES; MICE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; POTASSIUM CHANNEL BLOCKERS; RATS, SPRAGUE-DAWLEY; TORSADES DE POINTES;

EID: 84961771289     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149198     Document Type: Article

References (28)

1. Cubeddu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther. 2003;10(6):452-7. PMID: 14624285.
2. Raehl CL, Patel AK, Le Roy M. Drug-induced torsade de pointes. Clin Pharm. 1985;4(6):675-90. PMID: 2416504.
3. Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf. 2004;27(3):145-72. PMID: 14756578.
4. Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis. 2003;45(5):415-27. doi: 10.1053/pcad.2003.00101 PMID: 12704598.
5. Olsen KM. Pharmacologic agents associated with QT interval prolongation. J Fam Pract. 2005; Suppl:: S8-S14. PMID: 15938993.
6. Psaty BM. Clinical trial design and selected drug safety issues for antibiotics used to treat communityacquired pneumonia. Clin Infect Dis. 2008;47 Suppl 3:S176-9. doi: 10.1086/591400 PMID: 18986285; PubMed Central PMCID: PMCPMC2587028.
7. Anderson ME, Mazur A, Yang T, Roden DM. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther. 2001;296(3):806-10. PMID: 11181910.
8. Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ, et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther. 2008;84(4):475-80. PMID: 19238652.
9. Dale KM, Lertsburapa K, Kluger J, White CM. Moxifloxacin and torsade de pointes. Ann Pharmacother. 2007;41(2):336-40. doi: 10.1345/aph.1H474 PMID: 17284508.
10. Xu X, Yan GX, Wu Y, Liu T, Kowey PR. Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol. 2003;41(3):414-21. PMID: 12605020.
11. 2+ channel inactivation in controlling heart excitation. Proc Natl Acad Sci U S A. 2002;99(26):17185-90. doi: 10.1073/pnas.262372999 PMID: 12486220; PubMed Central PMCID: PMCPMC139290.
12. 2+ channels by azole antifungal agents in neonatal rat ventricular myocytes. Biol Pharm Bull. 2012;35(9):1469-75. PMID: 22975497.
13. Yoon JY, Ahn SH, Oh H, Kim YS, Ryu SY, Ho WK, et al. A novel Na+ channel agonist, dimethyl lithospermate B, slows Na+ current inactivation and increases action potential duration in isolated rat ventricular myocytes. Br J Pharmacol. 2004;143(6):765-73. doi: 10.1038/sj.bjp. 0705969 PMID: 15504759; PubMed Central PMCID: PMCPMC1575928.
14. Hille B. Ion channels of excitable membranes. 3rd ed. Sunderland, Mass.: Sinauer; 2001. xviii, 814 p. p.
15. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy. 2001;21(12):1468-72. PMID: 11765299.
16. Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol. 2001;59(1):122-6. PMID: 11125032.
17. Tsai WC, Tsai LM, Chen JH. Combined use of astemizole and ketoconazole resulting in torsade de pointes. J Formos Med Assoc. 1997;96(2):144-6. PMID: 9071844.
18. Zimmermann M, Duruz H, Guinand O, Broccard O, Levy P, Lacatis D, et al. Torsades de Pointes after treatment with terfenadine and ketoconazole. Eur Heart J. 1992;13(7):1002-3. PMID: 1644069.
19. Yang T, Chun YW, Stroud DM, Mosley JD, Knollmann BC, Hong C, et al. Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current. Circulation. 2014;130(3):224-34. doi: 10.1161/CIRCULATIONAHA.113.007765 PMID: 24895457; PubMed Central PMCID: PMCPMC4101031.
20. Hoffmann P, Warner B. Are hERG channel inhibition and QT interval prolongation all there is in druginduced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods. 2006;53(2):87-105. doi: 10.1016/j.vascn. 2005.07.003 PMID: 16289936.
21. Lu HR, Vlaminckx E, Hermans AN, Rohrbacher J, Van Ammel K, Towart R, et al. Predicting druginduced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br J Pharmacol. 2008;154(7):1427-38. doi: 10.1038/bjp. 2008.191 PMID: 18493243; PubMed Central PMCID: PMCPMC2440085.
22. Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C, Wang L, Hawryluk P, et al. Mechanisms of arsenicinduced prolongation of cardiac repolarization. Mol Pharmacol. 2004;66(1):33-44. doi: 10.1124/mol. 66.1.33 PMID: 15213294.
23. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther. 2005;312(1):316-23. doi: 10.1124/jpet.104.073692 PMID: 15340016.
24. Kuryshev YA, Wang L, Wible BA, Wan X, Ficker E. Antimony-based antileishmanial compounds prolong the cardiac action potential by an increase in cardiac calcium currents. Mol Pharmacol. 2006;69(4):1216-25. doi: 10.1124/mol.105.019281 PMID: 16418337.
25. Mahajan A, Sato D, Shiferaw Y, Baher A, Xie LH, Peralta R, et al. Modifying L-type calcium current kinetics: consequences for cardiac excitation and arrhythmia dynamics. Biophys J. 2008;94(2):411-23. doi: 10.1529/biophysj.106.98590 PMID: 18160661; PubMed Central PMCID: PMCPMC2157257.
26. 2+ channels. Biophys Chem. 2005;117(2):173-90. doi: 10.1016/j.bpc.2005.04.017 PMID: 15936868.
27. Ryu JS, Kim WT, Lee JH, Kwon JH, Kim HA, Shim EB, et al. Analysis of factors affecting Ca (2+)-dependent inactivation dynamics of L-type Ca (2+) current of cardiac myocytes in pulmonary vein of rabbit. J Physiol. 2012;590(Pt 18):4447-63. doi: 10.1113/jphysiol.2012.229203 PMID: 22674726; PubMed Central PMCID: PMCPMC3477751.
28. Budde T, Meuth S, Pape HC. Calcium-dependent inactivation of neuronal calcium channels. Nat Rev Neurosci. 2002;3(11):873-83. doi: 10.1038/nrn959 PMID: 12415295.